Regeneron Ireland Designated Activity Company (DAC) - Sökresultat

Europeiska unionen - svenska - EMA (European Medicines Agency)

libtayo

regeneron ireland designated activity company (dac) - cemiplimab - carcinom, squamous cell - antineoplastiska medel - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

rilonacept regeneron (previously arcalyst)

regeneron uk limited - rilonacept - cryopyrin-associerad periodiskt syndrom - immunsuppressiva - rilonacept regeneron är indicerat för behandling av kryopyrinassocierade periodiska syndrom (caps) med svåra symtom, inklusive familjär kall auto-inflammatoriska syndrom (familjärt fcas) och muckle-wells syndrom (mws), hos vuxna och barn 12 år och äldre.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

remeron-s 15 mg munsönderfallande tablett

nv organon - mirtazapin - munsönderfallande tablett - 15 mg - mannitol hjälpämne; aspartam hjälpämne; mirtazapin 15 mg aktiv substans; sockersfärer hjälpämne - mirtazapin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

remeron-s 15 mg munsönderfallande tablett

omnia läkemedel ab - mirtazapin - munsönderfallande tablett - 15 mg - mirtazapin 15 mg aktiv substans; aspartam hjälpämne; sockersfärer hjälpämne; mannitol hjälpämne - mirtazapin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

remeron 15 mg/ml oral lösning

nv organon - mirtazapin - oral lösning - 15 mg/ml - mirtazapin 15 mg aktiv substans; glycerol hjälpämne; maltitol, flytande hjälpämne; natriumbensoat hjälpämne - mirtazapin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)